UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 226,952 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 982,064 shares of the biopharmaceutical company's stock after purchasing an additional 226,952 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.89% of Regeneron Pharmaceuticals worth $699,554,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. OLD Second National Bank of Aurora raised its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares during the last quarter. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC raised its position in Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 15 shares during the last quarter. Manchester Capital Management LLC raised its position in Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 18 shares during the last quarter. Finally, Financial Perspectives Inc raised its position in Regeneron Pharmaceuticals by 10.9% during the 4th quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock valued at $137,000 after purchasing an additional 19 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 3.1%

REGN stock opened at $614.79 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $66.38 billion, a PE ratio of 16.06, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The business has a 50 day moving average of $596.79 and a 200 day moving average of $679.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the business earned $9.55 EPS. The firm's quarterly revenue was down 3.7% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.57%. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Analysts Set New Price Targets

A number of research firms have commented on REGN. Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Finally, Bank of America decreased their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.